NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Ontology highlight
ABSTRACT: Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. The current standard of care includes surgery followed by radiotherapy (RT) and chemotherapy with temozolomide (TMZ). Treatment often fails due to the radiation resistance and intrinsic or acquired TMZ resistance of a small percentage of cells with stem cell-like behavior (CSC). The NOTCH signaling pathway is expressed and active in human glioblastoma and NOTCH inhibitors attenuate tumor growth in vivo in xenograft models. Here we show using an image guided micro-CT and precision radiotherapy platform that a combination of the clinically approved NOTCH/γ-secretase inhibitor (GSI) RO4929097 with standard of care (TMZ + RT) reduces tumor growth and prolongs survival compared to dual combinations. We show that G
SUBMITTER: Yahyanejad S
PROVIDER: S-EPMC5173056 | biostudies-literature | 2016 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA